Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 19, 2011		May 31, 2012		May 31, 2011		May 31, 2010
OPERATING ACTIVITIES:
Net (loss) income	$ (6,374)		$ (49,647)		$ 89,327		$ 82,583
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	4,321		54,745		18,213		16,569
Non-cash interest expense			5,656
Loss on retirement of fixed assets	135		417		1,072		538
Provision for doubtful accounts	185		612		371		361
Share-based compensation expense	16,233		753		6,941		5,946
Deferred income taxes	(3,974)		(36,423)		941		4,994
Excess tax benefit from share-based compensation	0		0		(1,792)		183
Accrued refund of BioArray escrowed funds (1)		[1]		[1]	(4,256)	[1]		[1]
Changes in operating assets and liabilities:
Accounts receivable, trade	(3,938)		(5,347)		757		(6,386)
Income taxes	3,317		(414)		(2,790)		1,037
Inventories	(3,242)		12,219		(8,248)		(12,551)
Other assets	6,459		(2,469)		875		(102)
Accounts payable	(4,023)		5,601		2,412		(1,060)
Deferred revenue	(920)		(910)		(3,595)		(5,258)
Accrued expenses and other liabilities	17,409		5,614		1,883		(2,103)
Cash provided by (used in) operating activities	25,588		(9,593)		102,111		84,751
INVESTING ACTIVITIES:
Purchases of property and equipment	(2,265)		(5,964)		(9,061)		(6,304)
Acquisition of Immucor, Inc.			(1,939,387)
Purchase of licensing agreement			(99)
Cash used in investing activities	(2,265)		(1,945,450)		(9,061)		(6,304)
FINANCING ACTIVITIES:
Proceeds from long-term debt			991,406
Proceeds from capital contributions, net of costs			706,233
Payment of debt issuance costs			(42,474)
Repayments of long-term debt			(3,075)
Proceeds from revolving credit facility			11,000
Repayments of revolving credit facility			(11,000)
Repurchase of common stock	(458)				(526)		(11,910)
Proceeds from exercise of stock options	524				1,312		336
Excess tax benefit (shortfall) from share-based compensation					1,792		(183)
Cash provided by (used in) financing activities	66		1,652,090		2,578		(11,757)
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS	(3,029)		(1,432)		4,326		(502)
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	20,360		(304,385)		99,954		66,188
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	302,603		322,963		202,649		136,461
CASH AND CASH EQUIVALENTS AT END OF PERIOD	322,963		18,578		302,603		202,649
SUPPLEMENTAL INFORMATION:
Income taxes paid, net of refunds	3,414		8,918		43,090		36,295
Interest paid	0		50,366		0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Movement from inventory to property and equipment of instruments placed on rental agreements	1,618		12,392		12,857		13,733
Accrued refund of BioArray escrowed funds (1)					$ 2,935

[1] In fiscal 2011, the Company accrued the release of escrowed funds related to the acquisition of BioArray. In accordance with the contingent consideration guidance in Accounting Standards Codification ("ASC") 805 "Business Combinations," $2.9 million of the $7.2 million returned to the Company was recorded to Goodwill as it relates to items that were predefined as contingent items in the agreement pursuant to which the Acquisition occurred (the "Acquisition Agreement") and are considered measurement period adjustments. The $2.9 million appears in the Non-cash Investing and Financing Activities on the Consolidated Statement of Cash Flows. The remaining $4.3 million was recorded to Other Income as it is not considered a measurement period adjustment and appears as an adjustment to net income in the operating activities of the Consolidated Statement of Cash Flows. The funds were received by the Company during fiscal 2012.